Breast Cancer Drugs Market To Be Worth $19.96bn In 2020, New Visiongain Analysis Predicts

10 September 2018
Pharma

A new visiongain report forecasts that the global breast cancer drugs market will generate $19.96 billion in 2020. That revenue forecast and many others appear in Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals, published in March 2016. Visiongain is a business information publisher and consultancy based in London, UK.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said: “Breast cancer is the second most common cancer in the world, and by far the most common cancer among women. With the prevalence of the disease set to increase, a strong pipeline waiting to be launched, and the rising use of combination therapies to benefit both patients and manufacturers, we expect strong growth for this lucrative market.

“However, the breast cancer drugs market will also have to face patent expiries for various leading therapies during the forecast period and the looming threat of generic and biosimilar erosion, amongst other difficult challenges. As such, 2016-2026 is a crucial period for this market, one which will determine its long term future.”

Visiongain’s new analysis provides revenue forecasts for the global breast cancer drugs market from 2016 to 2026.

That study also gives revenue forecasts, specifically for the breast cancer indication, for nine leading drugs from 2016 to 2026:

• Herceptin (trastuzumab), Roche
• Perjeta (pertuzumab), Roche
• Afinitor (everolimus), Novartis
• Faslodex (fulvestrant), AstraZeneca
• Ibrance (palbociclib), Pfizer
• Avastin (bevacizumab), Roche
• Kadcyla (ado-trastuzumab emtansine), Roche
• Femara (letrozole), Novartis
• Abraxane (paclitaxel Protein-Bound), Celgene.

That investigation also provides overall forecasts for two classes of biosimilar: trastuzumab and bevacizumab.

The report also divides the overall market into its main therapeutic segments, showing revenue forecasts from 2016 to 2026 for these four submarkets:

• Monoclonal antibodies (mAbs)
• Chemotherapy and hormone therapy
• Kinase inhibitors
• Other medicines.
That work also assesses the current status of 18 of the most promising candidates in research and development. It also shows interviews with two companies. In addition, visiongain’s study provides revenue forecasts for 11 national breast cancer drug markets:

• The United States
• Japan
• Germany, France, Italy, the United Kingdom and Spain (EU5 countries)
• Brazil, Russia, India and China (BRIC group).

Breast Cancer Drugs Market 2016-2026: Revenue Forecasts for Monoclonal Antibodies, Hormones, Chemotherapy, Kinase Inhibitors and Other Pharmaceuticals adds to visiongain’s analysis on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.

Recent News

“Global Influenza Vaccines Market Set to Grow to $4.9bn by 2024” says new Visiongain report

The global vaccines market is one that is driven by innovation. This is vital for maintaining the rich pipeline of vaccines seen in the human vaccines market.

05 July 2019

Read

“Pharmaceutical Wholesale & Distribution Organizations 2019 is estimated to reach $1.4bn in 2024” says Visiongain report

Opportunities in the market stem from the increasing use of specialist and generic drugs, which have higher profit margins; global expansion into the emerging markets; vertical integration of wholesalers; and the increasing use of pharmaceuticals.

28 June 2019

Read

“Global Vaccines Sales market set to grow to $75bn by 2024” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs. This will also lead to more innovative approaches to vaccine development.

25 June 2019

Read

“Global Inflammatory Bowel Diseases (IBD) Drug Market is estimated to reach $8.6bn by 2024” says new Visiongain report

Revenue growth will be driven by rising incidence and prevalence owing to modern lifestyles and improved awareness and diagnosis.

21 June 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever